newsfilter
← Earnings
Earnings Releases·

Kailera Therapeutics — Third Quarter 2026 Earnings Summary

  • Net loss widened to $95.7 million for Q3 2026 from $39.6 million in the prior year period, driven by a $57.7 million increase in R&D expenses to $84.7 million and an $8.6 million rise in G&A to $21.7 million.
  • The company maintains a strong balance sheet with $1,037.6 million in cash and marketable securities, providing a runway into mid-2028 to support multiple value-creating inflection points.
  • Key clinical milestones are on track for 2027, including the initiation of the Ribupatide oral Phase 3 program in H1 2027, Ribupatide injection Phase 2b data in mid-2027, and Safiglipron Phase 2 data in mid-2027.
  • Significant capital restructuring occurred between December 2025 and September 2026, converting Series A and B preferred stock to zero and increasing additional paid-in capital from $11.9 million to $1,689.4 million.
Company
KAILERA THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology